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ABSTRACT 18 
Objectives. With the widespread use of antiseptics in healthcare facilities for the prevention 19 
of methicillin-resistant Staphylococcus aureus (MRSA) transmission, there are concerns for 20 
antiseptic tolerance and resistance. We sought to understand the use of chlorhexidine and 21 
octenidine, qac genes carriage and reduced antiseptic susceptibilities.  22 
Methods. A serial cross-sectional study was conducted in an acute care hospital and three 23 
extended-care facilities of a healthcare network in June-July, 2014-2016. Two of the 24 
extended-care facilities were exposed to intranasal octenidine and universal daily 25 
chlorhexidine/octenidine bathing. The minimum inhibitory concentration (MIC) levels and 26 
qac genes were determined by broth microdilution tests and whole genome sequencing 27 
respectively. Multivariable logistic regression was used to assess for the independent 28 
associations between antiseptic exposures, qac genes and reduced antiseptic susceptibilities. 29 
Results. A total of 878 MRSA isolates were obtained. There were associations between 30 
qacA/B carriage and chlorhexidine (adjusted odds ratio [aOR]: 7.80; 95% confidence interval 31 
[CI]: 3.25-18.71) and octenidine (aOR: 11.79; 95%CI: 5.14-27.04) exposures. Chlorhexidine 32 
exposure was associated with reduced chlorhexidine susceptibility (MIC≥4mg/L) (aOR: 3.15; 33 
95%CI: 1.14-8.74). Carriage of qacA/B (aOR: 10.65: 95%CI: 4.14-27.40) or qacC (aOR: 34 
2.55; 95%CI: 1.22-5.32) had an association with reduced chlorhexidine susceptibility; while 35 
MRSA sequence type modified the association. However, we found no direct association 36 
between (i) antiseptics use and qacC carriage, (ii) octenidine exposure and reduced 37 
susceptibility and (iii) reduced octenidine susceptibility and qacA/B or qacC carriage. 38 
Conclusions. Antiseptic exposures were associated with qac genes carriage. Chlorhexidine 39 
exposure was associated with reduced chlorhexidine susceptibility, requiring continued 40 
surveillance for the emergence of resistance.  41 
INTRODUCTION 42 
 Methicillin-resistant Staphylococcus aureus (MRSA), which predominantly resides in 43 
hospital environments and affects patients with serious underlying comorbidities, has been 44 
endemic in many parts of the world since the 1990s [1, 2]. MRSA remains a significant 45 
global threat for healthcare-associated infections since its discovery in the 1960s. Today, 46 
MRSA is responsible for 40-60% of all nosocomial Staphylococcus aureus infections [3]. 47 
MRSA-colonized individuals typically harbour the bacteria on mucocutaneous sites, most 48 
commonly in the nares, axillae, and groin. Carriage of MRSA can persist for years to 49 
decades, without any skin or wound infection [4]. Patient-to-patient direct and indirect 50 
transmission of MRSA within and between healthcare facilities have been well documented 51 
[5]. 52 
 To control for the MRSA transmission in hospitals, on-admission active surveillance 53 
screening and isolation of MRSA-colonized patients have been frequently adopted. 54 
Furthermore, antiseptic agents have been widely used, with MRSA decolonization guidelines 55 
including whole-body bathing with antiseptics and topical nasal application of mupirocin [6]. 56 
With the emergence of mupirocin resistance, octenidine has been used as an alternative for 57 
nasal decolonization [6]. Octenidine, cationic biguanide, is structurally similar to 58 
chlorhexidine but has a broader antibacterial activity spectrum towards Gram-positive 59 
bacteria [7]. 60 
 With the widespread use of antiseptics in healthcare settings, MRSA carrying proton 61 
motive force-dependent efflux pumps encoded by plasmid-borne qacA/B and qacC genes that 62 
confer resistance to cationic biocides such as chlorhexidine, have been reported [8]. 63 
However, reduced susceptibility to octenidine has yet to be reported. 64 
 Our study aims to assess for the association of the use of chlorhexidine and octenidine 65 
for the prevention of nosocomial MRSA transmission with the prevalence of (i) qacA/B and 66 
qacC genes and (ii) susceptibility to chlorhexidine and octenidine in MRSA isolated in an 67 
acute hospital and affiliated intermediate-care facilities in a healthcare network.  68 
METHODS 69 
Study Design and Setting 70 
 We conducted serial cross-sectional studies over three consecutive years from 2014 to 71 
2016, every six-week periods in June-July, in Tan Tock Seng Hospital (TTSH) and its three 72 
affiliated intermediate-term care facilities (ITCFs) in Singapore. TTSH is a 1600-bed adult 73 
acute tertiary-care hospital. The three ITCFs were included: (i) a 100-bed rehabilitation 74 
centre which specialized in managing patients with stroke, brain injury, spinal and 75 
musculoskeletal disorders (ITCF-1), (ii) a 360-bed community hospital providing care for 76 
patients with stroke and debilitating medical conditions (ITCF-2), and (iii) a 116-bed 77 
community hospital focused on inpatient care for stroke and subacute medical conditions 78 
(ITCF-3). 79 
Antiseptic exposure 80 
In ITCF-1, all inpatients were universally bathed daily with chlorhexidine 81 
(chlorhexidine gluconate 4%, Microshield*4, Johnson & Johnson, Australia) throughout the 82 
study period. From March to July 2016, a 5-day regimen of intranasal octenidine gel 83 
(octenidine hydrochloride 0.1%, Octenisan® md nasal gel, Schülke & Mayr GmbH, 84 
Norderstedt, Germany) was administered for MRSA-colonized patients from the day of 85 
admission to the ITCF. In ITCF-2, universal daily octenidine bathing (octenidine 86 
hydrochloride 0.3%, Octenisan® wash lotion, Schülke & Mayr GmbH, Norderstedt, 87 
Germany), with a 5-day application of intranasal octenidine (octenidine hydrochloride 0.1%, 88 
Octenisan® md nasal gel, Schülke & Mayr GmbH, Norderstedt, Germany) from day of 89 
admission for MRSA-colonized patients were implemented from March to July 2016. Prior to 90 
March 2016, ITCF-2 had not used any antiseptic products for MRSA decolonization. No 91 
antiseptic bathing or intranasal application was implemented in ITCF-3 and the acute care 92 
hospital (TTSH) throughout the study period. MRSA isolates were classified as being 93 
“exposed” or “unexposed” to chlorhexidine and octenidine respectively, depending on 94 
whether or not the isolates were obtained from patients who were exposed to chlorhexidine 95 
bathing and octenidine bathing/nasal gel. 96 
Participants and MRSA screening 97 
A randomly selected sample of 3,000 inpatients with ≥48-hour stay from the acute 98 
hospital who were systematically selected thrice over 15 days proportional to the bed census 99 
of the ward covering all wards, and all inpatients from ITCFs with ≥48-hour stay were 100 
included in the study. As the estimated mutation rate of one core single nucleotide 101 
polymorphism (SNPs) for MRSA is every six weeks [9], we completed the MRSA screening 102 
in all four institutions within six weeks each year. MRSA was screened with separate nasal, 103 
axillary and groin swabs taken by trained research nurses using a standardized protocol 104 
involving the use of swabs moistened with two sterile saline drops rolled five times in each 105 
nostril and ten times over the skin of the axillae and groin. The samples were inoculated onto 106 
selective chromogenic agar (Oxoid Brilliance MRSA2 Agar, Thermo Fisher Scientific, 107 
Basingstoke, United Kingdom) and incubated aerobically at 35-37°C for 18-24 hours at a 108 
common research laboratory. The results were read by the same medical technologist who 109 
was blinded to the origin of the samples, and hence the exposure to antiseptics. Growth of 110 
denim blue colonies were read as MRSA and referred to matrix assisted laser desorption 111 
ionization-time of flight (MALDI-TOF) mass spectrometry and cefoxitin disk diffusion test 112 
for confirmation of microbial identity and methicillin resistance.  113 
Susceptibility testing 114 
 Susceptibility of isolates to chlorhexidine and octenidine were determined by the 115 
minimum inhibitory concentration (MIC) levels using modified broth microdilution method, 116 
adhering to Clinical and Laboratory Standards Institute guidelines [10]. Fresh colonies were 117 
used and the range of susceptibility testing was from 0.125-8.0mg/L. Each isolate was tested 118 
in triplicates and incubated aerobically at 37oC for 16-20 hours.  119 
Whole genome sequencing 120 
DNA from the MRSA isolates were extracted using a commercial kit (DNeasy kit; 121 
Qiagen, Hilden, Germany) for whole genome sequencing. The detailed method was described 122 
elsewhere [11]. Briefly, DNA libraries were created using a method adapted from the 123 
Illumina Indexing standard protocol. Illumina readings were mapped onto relevant reference 124 
sequences using Sequence Search and Alignment by Hashing Algorithm (SSAHA) 125 
(version2.2.1) [12] and candidate SNPs were identified using ssaha_pileup [9]. A resistome 126 
database comprised of previously described database of known resistance determinant gene 127 
sequences, both horizontally acquired and core [13, 14]. Fastq files generated from 878 128 
isolates were mapped to the resistome database. Antimicrobial Resistance Identification By 129 
Assembly (ARIBA) (version2.12.1) [15] was run for resistance genes detection using the 130 
default settings. SNPs in chromosomal-encoded genes previously identified as being 131 
associated with antimicrobial resistance were then manually inspected to confirm the 132 
variation. 133 
Statistical analysis 134 
 Frequencies and percentages for categorical variables, and medians and interquartile 135 
ranges (IQR) for continuous variables, were used for descriptive analyses. Pearson’s χ2 or 136 
Fisher’s exact test for categorical variables and Mann-Whitney U test for continuous 137 
variables were used for bivariable analyses. Univariable and multivariable logistic regression 138 
were used to assess for the association between exposure to antiseptics, carriage of qac genes, 139 
and reduced antiseptic susceptibilities, while adjusting potential confounding variables. In the 140 
absence of an established cut-off for antiseptic resistance [16, 17], we pragmatically defined 141 
reduced susceptibility as an MIC level of ≥4mg/L for chlorhexidine and ≥2mg/L for 142 
octenidine for regression analyses. The odds ratio (OR) with 95% confidence interval (CI) 143 
from regression analyses were presented. All reported P values were two-tailed, with an α 144 
level of 0.05. Statistical analyses were conducted using Stata13.1 (CollegeStation, TX: 145 
StataCorp LP). 146 
RESULTS 147 
 We screened 5,456 patients who provided 878 MRSA isolates, of which 12% (n=106) 148 
and 14% (n=126) of isolates were respectively exposed to chlorhexidine and octenidine, for a 149 
median of 20 (IQR:6-49) and 28.5 (IQR:10-44) days. More MRSA were isolated from the 150 
ITCFs (n=528; 60.1%) than the acute care hospital (n = 350; 39.9%). Overall, about half 151 
(n=463; 52.7%) of the MRSA belonged to sequence type (ST)22, with the remaining being 152 
ST45 (n=290; 33.0%) and other STs (n=125; 14.3%). There were significant differences in 153 
sequence type of isolates between those exposed and unexposed to chlorhexidine (P<0.01) 154 
and octenidine (P<0.01) (Table1). 155 
Carriage of qac genes 156 
The overall period prevalence of qacA/B and qacC were 46.6% (n=409) and 13.6% 157 
(n=119) respectively. A significantly higher proportion of qacA/B was observed both in 158 
isolates exposed to (i) chlorhexidine (70.6% exposed v. 43.4% unexposed, P<0.001) and (ii) 159 
octenidine (65.1% exposed v. 43.5% unexposed, P<0.01).  However, qacC was more 160 
frequently detected in unexposed isolates to (i) chlorhexidine (4.9% exposed v. 14.7% 161 
unexposed, P<0.01) and (ii) octenidine (10.3% exposed v. 14.1% unexposed, P=0.25) 162 
(Table1). 163 
Among qacA/B carrying MRSA, majority of qacA/B was found in ST45 (n=287/409; 164 
70.2%), followed by ST22 (n=71/409; 17.3%) and other STs (n=51/409; 12.5%) MRSA. 165 
However, qacC was more prevalent in ST22 (n=74/119; 62.2%) than ST45 (n=2/119; 1.7%) 166 
and other STs (n=43/119; 36.1%). Stratifying the gene carriage by sequence types, a 167 
remarkably high proportion of ST45 carried qacA/B (n=287/290; 99.0%) compared to ST22 168 
(n=71/463; 15.3%) (Figure1). 169 
Minimum Inhibitory Concentration 170 
 The MIC ranged from 1-8mg/L for chlorhexidine and 0.5-2mg/L for octenidine. 171 
Chlorhexidine-exposed isolates had a higher proportion with reduced susceptibility 172 
(MIC≥4mg/L) to chlorhexidine than the unexposed ones (87.3% exposed v. 72.2% 173 
unexposed, P<0.01). However, there was no significant difference in the proportion with 174 
reduced susceptibility (MIC≥2mg/L) to octenidine between the octenidine-exposed and 175 
unexposed isolates (5.5% exposed v. 9.6% unexposed, P=0.14) (Table1). 176 
Associations between antiseptic exposure, qac genes carriage and reduced antiseptic 177 
susceptibility 178 
 Firstly, we examined the association between antiseptic exposure and qac genes 179 
carriage. After adjusting for healthcare facilities, year of isolation, sequence types and 180 
duration of exposure; chlorhexidine (adjusted odds ratio [aOR]:7.80, 95%CI: 3.25-18.71, 181 
P<0.001) and octenidine (aOR:11.79, 95%CI: 5.14-27.04, P<0.001) exposures were strongly 182 
associated with qacA/B. Although qacC carriage was negatively associated with exposure to 183 
chlorhexidine (aOR:0.18, 95%CI: 0.04-0.94, P=0.04), it was not significantly associated with 184 
exposure to octenidine (aOR:0.55, 95%CI: 0.23-1.31, P=0.18) (Table2). 185 
 Next, we investigated the relationship between antiseptic exposure and susceptibility. 186 
A significant reduction in antiseptic susceptibility was observed in chlorhexidine-exposed 187 
isolates, with three times as many exposed isolates as unexposed ones to have MIC levels 188 
≥4mg/L to chlorhexidine (aOR:3.15, 95%CI: 1.14-8.74, P=0.03). Interestingly, octenidine-189 
exposed isolates were nearly four times less likely than unexposed ones to have MIC≥2mg/L 190 
to octenidine (aOR:0.27, 95%CI: 0.08-0.95, P<0.01) (Table3). 191 
 Finally, we compared the carriage of qac genes with the prevalence of reduced 192 
antiseptic susceptibility. The odds of reduced chlorhexidine susceptibility increased in 193 
qacA/B (aOR:10.65, 95%CI: 4.14-27.40, P<0.001) and qacC (aOR:2.55, 95%CI: 1.22-5.32, 194 
P=0.01) carrying MRSA, compared to those without. However, neither the presence of 195 
qacA/B (aOR:0.76, 95%CI: 0.33-1.73, P=0.51) nor qacC (aOR:0.99, 95%CI: 0.43-2.31, 196 
P=0.99) were associated with reduced octenidine susceptibility (Table4). 197 
 In the secondary analysis, we further estimated the joint effects of qac genes and 198 
MRSA strains on chlorhexidine susceptibility (Table5). Using non-ST22/non-ST45/qac-199 
absent isolates as the reference, the odds of reduced chlorhexidine susceptibility for ST22 200 
without qacA/B was 4.12 (95%CI: 2.30-7.35, P<0.001) which increased to 28.60 (95%CI: 201 
3.66-223.57, P<0.01) in the presence of qacA/B. Both ST22 without qacC carriage 202 
(aOR:2.87, 95%CI: 1.64-5.03, P<0.001) and with qacC carriage (aOR:5.99, 95%CI: 1.93-203 
18.57, P<0.01) had increased odds of reduced chlorhexidine susceptibility. We found no 204 
association with reduced chlorhexidine susceptibility and ST45 with and without qacA/B or 205 
qacC. 206 
 We further assessed for the co-occurrence of resistance to mupirocin, an antibiotic 207 
commonly used for the decolonization of nasal carriage of MRSA. The mupirocin resistance 208 
gene, iles-2, was found in 10% (n=89) of our study MRSA isolates. We observed a 209 
significantly higher proportion of isolates carrying iles-2 in isolates with reduced 210 
susceptibility to chlorhexidine (12.6% MIC≥4mg/L v. 3.1% MIC<4mg/L, P<0.001), but not 211 
in isolates with reduced susceptibility to octendine (3.8% MIC≥2mg/L v. 10.8% 212 
MIC<2mg/L, P=0.05) (data not presented). 213 
DISCUSSION 214 
 In this study, we have demonstrated positive associations between (i) chlorhexidine/ 215 
octenidine exposures and qacA/B carriage (ii) chlorhexidine exposure and reduced 216 
susceptibility to chlorhexidine, and (iii) qacA/B and qacC carriages and reduced 217 
chlorhexidine susceptibility, and the modifying effects of qacA/B and qacC on ST22’s effects 218 
on reduced chlorhexidine susceptibility respectively. We further observed that neither 219 
octenidine exposure nor carriage of qacA/B or qacC genes was associated with reduced 220 
susceptibility to octenidine in our study’s isolates. On the contrary, isolates exposed to 221 
octenidine were four times less likely than unexposed isolates to have reduced susceptibility 222 
to octenidine.   223 
 The global distribution of qac genes is highly variable. One study reported that 224 
qacA/B can be found in 0.9-83.3% of clinical MRSA isolates worldwide [17]. Our study’s 225 
finding of qacA/B period prevalence of 46.6% was comparable to the prevalence of qacA/B 226 
observed in other Asian countries ranging from 24-61%, and higher than in Canada, the 227 
United States, and Scotland (1-15%) but lower than Brazil (80%) [18]. We detected qacC in 228 
13.6% of MRSA isolates, similar to other Asian studies ranging from 1-20%, but higher than 229 
the prevalence of 7% in Canada and 6% in Europe [18].  230 
Our findings on the association of chlorhexidine exposure and higher MIC levels to 231 
chlorhexidine, corroborated with observations by a study from the United Kingdom which 232 
described the correlation of chlorhexidine exposure with mean MIC levels of isolates 233 
including Staphylococcus aureus [19]. However, we did not find an association between 234 
octenidine exposure and higher MIC levels to octenidine. There have been limited published 235 
studies on octenidine exposure and susceptibility, although the effectiveness of octenidine as 236 
a decolonization regimen has been frequently reported [20-22].  237 
As described in other studies [23, 24], our study also indicated the association 238 
between antiseptic exposure and qacA/B carriage, although not with qacC carriage. Whilst we 239 
observed that qacA/B and qacC carriages were associated with reduced chlorhexidine 240 
susceptibility, we did not find an association between qac genes and reduced octenidine 241 
susceptibility. qacA/B is considered to be the most common gene encoding for resistance to 242 
biocides [25], and it significantly increases the risk of persistent MRSA carriage after 243 
decolonization therapy [26]. However, there have been suggestions that presence of qacA/B 244 
does not necessarily translate to the expression of reduced susceptibility to chlorhexidine 245 
[18]. Although almost all (99%) of our ST45 MRSA carried qacA/B, they were not positively 246 
associated with reduced susceptibility to chlorhexidine. Whilst the qacA/B carriage rate in 247 
ST22 (15%) was low, ST22 was positively associated with reduced susceptibility to 248 
chlorhexidine, consistent with findings from a recent study conducted in the United Kingdom 249 
[22]. An Australian study evaluating 123 MRSA isolates also noted the over-predominance 250 
of ST22 in the expression of reduced susceptibility to chlorhexidine [27]. The reason behind 251 
raised MIC levels in certain MRSA strains remains unclear. However, possible alternate 252 
mechanisms includes overexpression of mutant chromosomally encoded genes of efflux 253 
pump such as norA, norB and mepA [8, 18]. An in vitro study demonstrated the increased 254 
expression of the efflux pump genes in clinical isolates when exposed to low concentrations 255 
of antiseptics [28]. Future studies are required to elucidate the differences in resistance 256 
mechanisms between MRSA strains. For ST22 and STs other than ST45, we further observed 257 
that the presence of qacA/B and qacC genes enhanced the effects of the respective MRSA 258 
clones on reduced susceptibility to chlorhexidine. Whilst the observed clonal predominance 259 
of qac genes corroborated with other studies [23, 29], the modifying effects of qac genes on 260 
the effects of specific MRSA clones on antiseptic resistance have not been reported 261 
previously. 262 
Our study has several strengths. To our knowledge, this is the first clinical study 263 
reporting octenidine susceptibility in MRSA from acute- and intermediate-care settings in a 264 
healthcare network. Secondly, we demonstrated the joint effects of MRSA strains and qac 265 
genes on reduced chlorhexidine susceptibility, providing new observations that can advance 266 
the understanding of antiseptic resistance in MRSA with further studies. Thirdly, samples 267 
were collected by trained research nurses who followed standardized procedures, tested in a 268 
single laboratory by the same medical technologist, and were confirmed with MALDI-TOF 269 
minimizing any potential measurement error and misclassification. Fourthly, blinded 270 
microbiologic assessment of samples reduced any potential detection bias. Finally, our 271 
MRSA clones were consistent with the epidemiology of MRSA in Singapore, rendering any 272 
potential selection bias unlikely [11, 30]. 273 
 There are several limitations. We acknowledge that the MIC cut-off we used to define 274 
reduced susceptibility might not be internationally adopted. Nonetheless, studies have defined 275 
chlorhexidine MIC≥4mg/L to represent reduced susceptibility [18, 22]. To date, no study has 276 
determined the MIC cut-off for octenidine. Hence, we selected the most plausible cut-off of 277 
MIC≥2mg/L to define reduced octenidine susceptibility for our study. Likewise, there have 278 
not been any standard definition nor standardized methods to determine antiseptic resistance. 279 
Whilst the majority of published literature have adopted MIC-based methods for antiseptic 280 
susceptibility testing, minimum bactericidal concentration (MBC) has been suggested by 281 
some papers to better reflect clinical outcomes. We have chosen to determine MIC levels in 282 
this study for comparability with other studies. Furthermore, we did not test for other 283 
mechanisms of antiseptic resistance including norA/B and there could be residual 284 
confounding due to unknown confounders despite adjusting for key confounders defined a 285 
prior in the multivariable regression analyses. 286 
 In summary, chlorhexidine and octenidine are essential antiseptics used in the 287 
prevention and control of MRSA in healthcare settings worldwide. This study provided 288 
evidence of reduced susceptibility to chlorhexidine with exposure, although we did not find a 289 
reduction with octenidine. This finding has important clinical implications, as more 290 
healthcare institutions implement universal chlorhexidine and octenidine bathing programs to 291 
prevent nosocomial MRSA transmission. 292 
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Figure 1. Distribution of different methicillin-resistant Staphylococcus aureus sequence types carrying qacA/B & qacC genes based on A. 397 
chlorhexidine exposure, and  B. octenidine exposure  398 
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Table 1. Characteristics of methicillin-resistant Staphylococcus aureus isolates from the acute- and intermediate-term care facilities 399 
 
Characteristics 
 
Total isolates 
(n = 878) 
Chlorhexidine Octenidine 
Exposed 
isolates* 
(n = 102) 
Unexposed 
isolates* 
(n = 776) 
P1 Exposed 
isolates* 
(n = 126) 
Unexposed 
isolates* 
(n = 752) 
P2 
Healthcare institutions 
   
<0.001 
  
<0.001 
     ACH 350 (39.9) 0 350 (45.1) 
 
0 350 (46.5) 
 
     ITCF-1 102 (11.6) 102 (100.0) 0 
 
17 (13.5) 85 (11.3) 
 
     ITCF-2 330 (37.6) 0 330 (42.5) 
 
109 (86.5) 221 (29.4) 
 
     ITCF-3 96 (10.9) 0 96 (12.4) 
 
0 96 (12.8) 
 
Healthcare facilities 
   
<0.001 
  
<0.001 
     ACH 350 (39.9) 0 350 (45.1) 
 
0 350 (46.5) 
 
     ITCFs 528 (60.1) 102 (100.0) 426 (54.9) 
 
126 (100.0) 402 (53.5) 
 
Year of MRSA isolation 
   
<0.001 
  
<0.001 
     2014 43 (4.9) 43 (42.1) 0 
 
0 43 (5.7) 
 
     2015 497 (56.6) 42 (41.2) 455 (58.6) 
 
0 497 (66.1) 
 
     2016 338 (38.5) 17 (16.7) 321 (41.4) 
 
126 (100.0) 212 (28.2) 
 
Duration of antiseptic exposure, days 
       
     median (IQR) − 20 (6 - 49) − − 28.5 (10 - 44) − − 
Sequence type 
   
<0.01 
  
<0.01 
     ST22 463 (52.7) 51 (50.0) 412 (53.1) 
 
77 (61.1) 386 (51.3) 
 
     ST45 290 (33.0) 45 (44.1) 245 (31.6) 
 
45 (35.7) 245 (32.6) 
 
     Other STs# 125 (14.3) 6 (5.9) 119 (15.3) 
 
4 (3.2) 121 (16.1) 
 
Carriage of qacA/B genes 409 (46.6) 72 (70.6) 337 (43.4) <0.001 82 (65.1) 327 (43.5) <0.001 
Carriage of qacC genes 119 (13.6) 5 (4.9) 114 (14.7) <0.01 13 (10.3) 106 (14.1) 0.25 
MIC level to chlorhexidine 
   
<0.01† 
  
− 
     1 mg/L 11 (1.3) 0 11 (1.4) 
 
− − 
 
     2 mg/L 218 (24.8) 13 (12.7) 205 (26.4) 
 
− − 
 
     4 mg/L 647 (73.7) 88 (86.3) 559 (72.1) 
 
− − 
 
     8 mg/L 2 (0.2) 1 (1.0) 1 (0.1) 
 
− − 
 
MIC level to chlorhexidine ≥ 4mg/L 649 (73.9) 89 (87.3) 560 (72.2) <0.01 − − 
 
MIC level to octenidine 
   
− 
  
0.15† 
     0.5 mg/L 3 (0.3) − − 
 
1 (0.8) 2 (0.3) 
 
     1 mg/L 796 (90.7) − − 
 
118 (93.6) 678 (90.1) 
 
     2 mg/L 79 (9.0) − − 
 
7 (5.6) 72 (9.6) 
 
MIC level to octenidine ≥ 2mg/L 79 (9.0) − − − 7 (5.6) 72 (9.6) 0.14 
Abbreviations: ACH, Acute care hospital; IQR, Interquartile range; ITCFs, Intermediate-term care facilities; MIC, Minimum inhibitory 400 
concentration; ST, sequence type. 401 
*MRSA isolates were classified as being “exposed” or “unexposed” to chlorhexidine and octenidine respectively, depending on whether or not 402 
the isolates were obtained from patients who were exposed to chlorhexidine bathing and octenidine bathing/nasal gel. 403 
Values are expressed in no. (%) unless stated otherwise 404 
P1; statistical test between chlorhexidine exposed and unexposed isolates 405 
P2; statistical test between octenidine exposed and unexposed isolates 406 
#Other STs include ST5 (n=1), ST6 (n=3), ST59 (n=1), ST80 (n=1), ST88 (n=1), ST188 (n=1), ST239 (n=45), ST573 (n=17), ST622 (n=37), 407 
ST672 (n=1), ST1178 (n=5), ST1218 (n=2), ST1232 (n=1), NF (n=9) 408 
†; Fisher's exact test  409 
Table 2. Associations between chlorhexidine and octenidine exposures and carriage of qacA/B and qacC genes among methicillin-resistant 410 
Staphylococcus aureus isolates 411 
aadjusted for year, facility of MRSA isolate detection, duration of exposure and sequence type (categorized as ST22, ST45 and other STs)  412 
Variables Total isolates 
(n = 878) 
Isolates carrying qac genes  
[no./total no. (%)] 
Crude odds ratio 
(95% CI) 
P Adjusted odds ratioa 
(95% CI) 
P 
 
C
h
lo
r
h
ex
id
in
e 
qacA/B genes 
Unexposed 776 (88.4) 337/776 (43.4) Reference Reference 
Exposed 102 (11.6) 72/102 (70.6) 3.13 (1.99 - 4.90) <0.001 7.80 (3.25 - 18.71) <0.001 
qacC genes 
Unexposed 776 (88.4) 114/776 (14.7) Reference Reference 
Exposed 102 (11.6) 5/102 (4.9) 0.30 (0.12 - 0.75) 0.01 0.18 (0.04 - 0.94) 0.04 
O
ct
en
id
in
e 
qacA/B genes  
Unexposed 752 (85.6) 327/752 (43.5) Reference Reference 
Exposed 126 (14.4) 82/126 (65.1) 2.42 (1.63 - 3.59) <0.001 11.79 (5.14 - 27.04) <0.001 
qacC genes  
Unexposed 752 (85.6) 106/752 (14.1) Reference Reference 
Exposed 126 (14.4) 13/126 (10.3) 0.70 (0.38 - 1.29) 0.25 0.55 (0.23 - 1.31) 0.18 
Table 3. Associations between chlorhexidine and octenidine exposures and reduced antiseptic susceptibility among methicillin-resistant 413 
Staphylococcus aureus isolates 414 
Variables Total isolates 
(n = 878) 
Isolates with reduced 
antiseptic susceptibilitya 
[no./total no. (%)] 
Crude odds ratio 
(95% CI) 
P Adjusted odds ratiob 
(95% CI) 
P 
Chlorhexidine exposure 
Unexposed 776 (88.4) 560/776 (72.2) Reference Reference 
Exposed 102 (11.6) 89/102 (87.3) 2.64 (1.45 - 4.82) <0.01 3.15 (1.14 - 8.74) 0.03 
Octenidine exposure  
Unexposed 752 (85.6) 72/752 (9.6) Reference Reference 
Exposed 126 (14.4) 7/126 (5.6) 0.56 (0.25 - 1.24) 0.15 0.27 (0.08 - 0.95) <0.01 
 areduced antiseptic susceptibility is defined as MIC ≥4mg/L for chlorhexidine, and MIC ≥2mg/L for octenidine 415 
badjusted for year, facility of MRSA isolate detection, duration of exposure, sequence type (categorized as ST22, ST45 and other STs), and 416 
presence of qacA/B and qacC genes  417 
Table 4. Associations between carriage of qacA/B and qacC genes and reduced chlorhexidine and octenidine susceptibility among methicillin-418 
resistant Staphylococcus aureus isolates 419 
Variables Isolates susceptible 
to antiseptic  
[no./total no. (%)] 
Isolates with reduced 
antiseptic susceptibilitya 
[no./total no. (%)] 
Crude odds ratio 
(95% CI) 
P Adjusted odds ratiob 
(95% CI) 
P 
C
h
lo
rh
ex
id
in
e 
qacA/B genes 
qacA/B – 92/229 (40.2) 377/649 (58.1) Reference Reference 
qacA/B + 137/229 (59.8) 272/649 (41.9) 0.48 (0.36 - 0.66) <0.001 10.65 (4.14 - 27.40) <0.001 
qacC genes 
qacC – 219/229 (95.6) 540/649 (83.2) Reference Reference 
qacC + 10/229 (4.4) 109/649 (16.8) 4.42 (2.27 - 8.61) <0.001 2.55 (1.22 -  5.32) 0.01 
O
ct
en
id
in
e 
qacA/B genes 
qacA/B – 430/799 (53.8) 39/79 (49.4) Reference Reference 
qacA/B + 369/799 (46.2) 40/79 (50.6) 1.19 (0.75 - 1.90) 0.45 0.76 (0.33 - 1.73) 0.51 
qacC genes 
qacC – 688/799 (86.1) 71/79 (89.9) Reference Reference 
qacC + 111/799 (13.9) 8/79 (10.1) 0.70 (0.33 - 1.49) 0.35 0.99 (0.43 - 2.31) 0.99 
areduced antiseptic susceptibility is defined as MIC ≥4mg/L for chlorhexidine, and MIC ≥2mg/L for octenidine. 420 
badjusted for year, facility of MRSA isolate detection, sequence types (categorized as ST22, ST45 and other STs), antiseptic exposure and 421 
duration of exposure  422 
Table 5. Joint association of qacA/B or qacC carriage and sequence types (ST), and reduced chlorhexidine susceptibility among methicillin-423 
resistant Staphylococcus aureus isolates 424 
 qac genes & ST Isolates susceptible 
to chlorhexidine  
(MIC <4 mg/L) 
(n = 229) 
Isolates with reduced 
chlorhexidine susceptibility  
(MIC ≥4 mg/L) 
(n = 649) 
Crude odds ratio 
(95% CI) 
P Adjusted odds ratioa 
(95% CI) 
P 
q
a
c
A
/B
 g
en
es
 
qacA/B – & other ST 30 (13.1) 44 (6.8) Reference Reference 
qacA/B – & ST45 3 (1.3) 0 (0.0) – – 
qacA/B – & ST22 59 (25.8) 333 (51.3) 3.85 (2.24 - 6.61) <0.001 4.12 (2.30 - 7.35) <0.001 
qacA/B + & other ST 5 (2.2) 46 (7.1) 6.27 (2.23 - 17.62) <0.001 10.37 (3.53 - 30.46) <0.001 
qacA/B + & ST45 131 (57.2) 156 (24.0) 0.81 (0.48 - 1.36) 0.43 0.62 (0.35 - 1.10) 0.11 
qacA/B + & ST22 1 (0.4) 70 (10.8) 47.73 (6.28 - 362.57) <0.001 28.60 (3.66 - 223.57) <0.01 
q
a
cC
 g
en
es
 
qacC – & other ST 31 (13.5) 51 (7.9) Reference Reference 
qacC – & ST45 132 (57.6) 156 (24.0) 0.72 (0.43 - 1.19) 0.20 0.43 (0.25 - 0.74) <0.01 
qacC – & ST22 56 (24.5) 333 (51.3) 3.61 (2.13 - 6.13) <0.001 2.87 (1.64 - 5.03) <0.001 
qacC + & other ST 4 (1.7) 39 (6.0) 5.93 (1.93 - 18.19) <0.01 4.93 (1.55 - 15.69) <0.01 
qacC + & ST45 2 (0.9) 0 (0.0) – – 
qacC + & ST22 4 (1.8) 70 (10.8) 10.64 (3.53 - 32.02) <0.001 5.99 (1.93 - 18.57) <0.01 
aadjusted for year, facility of MRSA isolate detection, chlorhexidine exposure and duration of exposure 425 
